The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia

Background: Immunophenotyping improves both accuracy and reproducibility of acute leukemia classification and is considered, particularly useful for identifying acute myeloid leukemia (AML) with lymphoid marker expression. The incidence of the aberrant phenotypes in AML is still controversial; incid...

Full description

Bibliographic Details
Main Authors: Wafaa Mohammed Al-Anizi, Mohammed Abdul Rassoul Al-Mashta
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Iraqi Journal of Hematology
Subjects:
Online Access:http://www.ijhonline.org/article.asp?issn=2072-8069;year=2017;volume=6;issue=2;spage=49;epage=54;aulast=Al-Anizi
id doaj-3619578f052b45758835280af0955a63
record_format Article
spelling doaj-3619578f052b45758835280af0955a632020-11-24T22:48:53ZengWolters Kluwer Medknow PublicationsIraqi Journal of Hematology2072-80692017-01-0162495410.4103/ijh.ijh_17_17The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemiaWafaa Mohammed Al-AniziMohammed Abdul Rassoul Al-MashtaBackground: Immunophenotyping improves both accuracy and reproducibility of acute leukemia classification and is considered, particularly useful for identifying acute myeloid leukemia (AML) with lymphoid marker expression. The incidence of the aberrant phenotypes in AML is still controversial; incidences as high as 88% have been reported. Objectives: To evaluate the occurrence of aberrant lymphoid phenotypes and to correlate their presence with various French-American-British classification (FAB subtypes), 202 cases of newly diagnosed AML were analyzed for lymphoid markers CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, and CD79a. Materials And Methods: Whole blood or bone marrow aspirate of 202 patients with de novo AML was collected in ethylenediaminetetraacetic acid tube and analyzed by flow cytometry using a large panel of fluorochrome-labeled monoclonal antibodies. Identification of blast cells was performed using forward scatter versus side scatter (SSC) parameters and CD45 intensity versus SSC dot plots. An antigen was considered positively expressed when at least 20% of the gated cells expressed that antigen. Results: Eighty-five patients (42%) with de novo AML expressed lymphoid-associated antigens. All AML subtypes demonstrated lymphoid-associated antigens except M7. T-cell aberrancy was the most common comprising 32.2% of the total aberrancy. The most frequently lymphoid antigen aberrantly expressed was CD7 (25.7%), followed by CD4 (22.4%) and CD19 (7.9%). Conclusion: A large number of AML cases showed aberrant lymphoid phenotypes. These lymphoid phenotypes might be associated with different leukemia subtypes. T-cell markers are more common than B-cell markers. CD7 was the most common lymphoid marker aberrantly expressed in AML.http://www.ijhonline.org/article.asp?issn=2072-8069;year=2017;volume=6;issue=2;spage=49;epage=54;aulast=Al-AniziAcute myeloid leukemiade novoIraqilymphoidmarkers
collection DOAJ
language English
format Article
sources DOAJ
author Wafaa Mohammed Al-Anizi
Mohammed Abdul Rassoul Al-Mashta
spellingShingle Wafaa Mohammed Al-Anizi
Mohammed Abdul Rassoul Al-Mashta
The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia
Iraqi Journal of Hematology
Acute myeloid leukemia
de novo
Iraqi
lymphoid
markers
author_facet Wafaa Mohammed Al-Anizi
Mohammed Abdul Rassoul Al-Mashta
author_sort Wafaa Mohammed Al-Anizi
title The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia
title_short The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia
title_full The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia
title_fullStr The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia
title_full_unstemmed The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia
title_sort frequency of aberrant lymphoid antigens expression in 202 iraqi patients with de novo acute myeloid leukemia
publisher Wolters Kluwer Medknow Publications
series Iraqi Journal of Hematology
issn 2072-8069
publishDate 2017-01-01
description Background: Immunophenotyping improves both accuracy and reproducibility of acute leukemia classification and is considered, particularly useful for identifying acute myeloid leukemia (AML) with lymphoid marker expression. The incidence of the aberrant phenotypes in AML is still controversial; incidences as high as 88% have been reported. Objectives: To evaluate the occurrence of aberrant lymphoid phenotypes and to correlate their presence with various French-American-British classification (FAB subtypes), 202 cases of newly diagnosed AML were analyzed for lymphoid markers CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, and CD79a. Materials And Methods: Whole blood or bone marrow aspirate of 202 patients with de novo AML was collected in ethylenediaminetetraacetic acid tube and analyzed by flow cytometry using a large panel of fluorochrome-labeled monoclonal antibodies. Identification of blast cells was performed using forward scatter versus side scatter (SSC) parameters and CD45 intensity versus SSC dot plots. An antigen was considered positively expressed when at least 20% of the gated cells expressed that antigen. Results: Eighty-five patients (42%) with de novo AML expressed lymphoid-associated antigens. All AML subtypes demonstrated lymphoid-associated antigens except M7. T-cell aberrancy was the most common comprising 32.2% of the total aberrancy. The most frequently lymphoid antigen aberrantly expressed was CD7 (25.7%), followed by CD4 (22.4%) and CD19 (7.9%). Conclusion: A large number of AML cases showed aberrant lymphoid phenotypes. These lymphoid phenotypes might be associated with different leukemia subtypes. T-cell markers are more common than B-cell markers. CD7 was the most common lymphoid marker aberrantly expressed in AML.
topic Acute myeloid leukemia
de novo
Iraqi
lymphoid
markers
url http://www.ijhonline.org/article.asp?issn=2072-8069;year=2017;volume=6;issue=2;spage=49;epage=54;aulast=Al-Anizi
work_keys_str_mv AT wafaamohammedalanizi thefrequencyofaberrantlymphoidantigensexpressionin202iraqipatientswithdenovoacutemyeloidleukemia
AT mohammedabdulrassoulalmashta thefrequencyofaberrantlymphoidantigensexpressionin202iraqipatientswithdenovoacutemyeloidleukemia
AT wafaamohammedalanizi frequencyofaberrantlymphoidantigensexpressionin202iraqipatientswithdenovoacutemyeloidleukemia
AT mohammedabdulrassoulalmashta frequencyofaberrantlymphoidantigensexpressionin202iraqipatientswithdenovoacutemyeloidleukemia
_version_ 1725678369538834432